Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/3228
Title: CYTOTOXIC EFFECT OF INTERLEUKIN-8 IN RETINAL GANGLION CELLS AND ITS POSSIBLE MECHANISMS
Authors: Jing-Jing, W.
Walana, W.
Bing, W.
Jing, W.
Xia, L.
Jya-Wei, C.
John, G. R.
Jing-Min, L.
Fang, L.
Keywords: glaucoma
inflammation
interleukin-8
retinal ganglion cell-5
apoptosis
G31P
Issue Date: 2018
Publisher: International journal of ophthalmology Press Co., Limited
Abstract: ● AIM: To investigate the effect of interleukin-8 (IL-8) on neural retinal ganglion cells (RGCs) and whether it can be alleviated by G31P. ● METHODS: RGC-5 cells were exposed to IL-8 with or without its specific receptor antagonist G31P for 24h, and the cell viability was assessed by Cell Counting Kit 8 (CCK-8). Apoptosis was measured by examining nuclear morphology and quantifying with flow cytometry. Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and Western blot were used to investigate the expression of apoptosis-related genes. ● RESULTS: CCK-8 assay showed that IL-8 significantly inhibits the viability of RGC-5 cells in a dose-dependent manner. Cell apoptosis assays exhibited higher apoptotic rate in IL-8 treatment group compared to control group. We further found that IL-8 could promote Bax and caspase-3 expressions, but decrease the level of Bcl-2 in the aspect of mRNA and protein. However, pre-treatment with G31P partly attenuated these effects in RGC-5 cells (P<0.05). ● CONCLUSION: These results indicate that anti-proliferation effects of IL-8 through induction of cell apoptosis regulated by Bcl-2, Bax and caspase-3 expressions, can be ameliorated by G31P.
URI: http://hdl.handle.net/123456789/3228
ISSN: 2227-4898
Appears in Collections:School of Medicine and Health Sciences

Files in This Item:
File Description SizeFormat 
CYTOTOXIC EFFECT OF INTERLEUKIN-8 IN RETINAL GANGLION CELLS AND ITS POSSIBLE MECHANISMS.pdf1.25 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.